Photo by karolinabobek from unsplash
In a regulatory first, the FDA has collaboratively reviewed a new cancer treatment with drug agencies in Canada and Australia, allowing for simultaneous approval of lenvatinib in combination with pembrolizumab… Click to show full abstract
In a regulatory first, the FDA has collaboratively reviewed a new cancer treatment with drug agencies in Canada and Australia, allowing for simultaneous approval of lenvatinib in combination with pembrolizumab for the treatment of recurrent endometrial carcinomas.
Keywords:
collaborative review;
approval;
concurrent approval;
review concurrent
Journal Title: Cancer discovery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!